Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

Published:2022-09-05 Issue:2 Volume:12 Page:202-211
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Parmar Deven V.¹,Kansagra Kevinkumar A.²,Momin Taufik¹,Patel Hardik B.²,Jansari Gaurav A.²,Bhavsar Jay²,Shah Chintan²,Patel Jayesh M.²,Ghoghari Ashok²,Barot Ajay²,Sharma Bhavesh²,Viswanathan Kasinath²,Patel Harilal V.²,Jain Mukul R.²

Affiliation:

1. Zydus Therapeutics Inc Pennington New Jersey USA

2. Zydus Research Centre Zydus Lifesciences Limited Ahmedabad Gujarat India

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1162

Reference19 articles.

1. NLRP3 inflammasome and its inhibitors: a review

2. Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors